Background Both fosinopril and valsartan are effective in protecting endothelial function. We
hypothesized that they may also reduce myocardial no-reflow. In addition, suppression of …

Simvastatin can prevent cardiac remodelling after myocardial infarction, though the exact
mechanisms are uncertain. Myocardial no‐reflow is associated with progressive cardiac …

Objective: To compare the effects of an aspirin–clopidogrel combination with those of the
specific glycoprotein IIb/IIIa inhibitor tirofiban on myocardial no-reflow, nitric oxide …

Background Adenosine and calcium channel blockers have been used in the treatment of
angiographic no-reflow directly after angioplasty for acute myocardial infarction (AMI) …

It has been verified that carvedilol can attenuate myocardial no-reflow. However, the effects
of carvedilol on adenosine triphosphate-sensitive K+ (KATP) channel and endothelin-1 (ET …

Objective: We aimed to investigate the effects of verapamil and adenosine in an adjunct to
intravenous tirofiban on management and prognosis of noreflow phenomenon during …

Objectives: This study aimed to clarify the role of adenosine triphosphate-sensitive K+
(KATP) channels in the no-reflow phenomenon and in its extension by …

INTRODUCTION: It has been found that nicorandil can attenuate myocardial no-reflow.
However, the exact cause of this beneficial effect has remained unclear. We investigated …

Objective To investigate the effects of tirofiban on the no-reflow phenomenon of acute
myocardial infarction (AMI) rats received reperfusion, as well as the underlying mechanisms …

Original Article Prevention of No Flow/Slow Reflow Phenomenon in Primary PCI by Nicorandil
Page 1 Indian Heart J 2007; 59 (3): 246 – 249 Original Article Prevention of No Flow/Slow …